EICIX
Price
$18.49
Change
+$0.05 (+0.27%)
Updated
Jun 2 closing price
Net Assets
366.65M
RMEBX
Price
$62.83
Change
+$0.38 (+0.61%)
Updated
Jun 2 closing price
Net Assets
114.65B
Interact to see
Advertisement

EICIX vs RMEBX

Header iconEICIX vs RMEBX Comparison
Open Charts EICIX vs RMEBXBanner chart's image
EICIX vs RMEBX Comparison Chart in %
View a ticker or compare two or three
VS
EICIX vs. RMEBX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EICIX is a Hold and RMEBX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 115B vs. EICIX (367M). EICIX pays higher dividends than RMEBX: EICIX (2.19) vs RMEBX (1.04). EICIX was incepted earlier than RMEBX: EICIX (15 years) vs RMEBX (12 years). RMEBX (1.07) is less costly to investors than EICIX (0.98). RMEBX (30.00) and EICIX (29.00) have comparable annual turnover. RMEBX has a lower initial minimum investment than EICIX: RMEBX (250) vs EICIX (10000). RMEBX annual gain was more profitable for investors over the last year : 9.98 vs. EICIX (4.67). RMEBX return over 5 years is better than : 32.93 vs. EICIX (19.22).
EICIXRMEBXEICIX / RMEBX
Total Expense Ratio0.961.0790%
Annual Report Gross Expense Ratio0.981.0792%
Fund Existence15 years12 years-
Gain YTD3.0175.80152%
Front LoadN/AN/A-
Min. Initial Investment100002504,000%
Min. Initial Investment IRAN/AN/A-
Net Assets367M115B0%
Annual Yield % from dividends2.191.04211%
Returns for 1 year4.679.9847%
Returns for 3 years32.4534.1495%
Returns for 5 years19.2232.9358%
Returns for 10 years65.5089.8473%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HOVNP20.810.08
+0.36%
Hovnanian Enterprises
BLD407.07-5.12
-1.24%
TopBuild Corp
IMOS64.61-1.96
-2.94%
ChipMOS TECHNOLOGIES
FLNA1.44-0.05
-3.36%
Filana Therapeutics Inc
OVID2.40-0.16
-6.25%
Ovid Therapeutics